Wall Street is positive on ORIC Pharmaceuticals Inc (ORIC). On average, analysts give the stock a Buy rating. The average price target is $19, which means analysts expect the stock to add by 365.69% over the next twelve months. That average ranking earns the stock an Analyst Rating of 29, which is better than 29% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating ORIC a Buy today. Find out what this means to you and get the rest of the rankings on ORIC!